Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625145 | 0.97 | ALOX5 (0.61) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL4626181 | 0.93 | ALOX5 (0.57) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL5560476 | 0.93 | ALOX5 (0.57) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL4625128 | 0.93 | ALOX5 (0.76) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL14586194 | 0.93 | ALOX5 (0.57) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL4626142 | 0.91 | ALOX5 (0.57) | ALOX5KMT2APKMPOLBPTGES | |
| SCHEMBL4625346 | 0.90 | ALOX5 (0.64) | ALOX5KMT2APOLBPTGESMAPT | |
| SCHEMBL4625225 | 0.88 | ALOX5 (0.58) | ALOX5KMT2APOLBPTGESMAPT | |
| SCHEMBL5560556 | 0.88 | NPC1 (0.54) | ALOX5KMT2APKMPOLBMAPT | |
| SCHEMBL4626127 | 0.88 | ALOX5 (0.61) | ALOX5PTGESMAPTGAAHGFAC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1635812-A2 | BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005004799-A2 | β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | ACE, ACE2, CTRL | ALOX5 1853/4885KMT2A 3018/4885PKM 3060/4885 |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | LCT, BCHE, GAA | ALOX5 615/4885KMT2A 1341/4885PKM 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.